Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

56.22 -0.46 (-0.81%)
Streaming Delayed Price Updated: 1:34 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Peering Into Biomarin Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
CAMP4 Analyst Highlights Rare Disease Platform Potential ↗
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036. 
Via Benzinga
Topics Initial Public Offering
News headline image
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth ↗
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
Via Benzinga
News headline image
In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast ↗
 
Via Benzinga
News headline image
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗
NASDAQ:BMRN is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
How Is The Market Feeling About Biomarin Pharmaceutical? ↗
 
Via Benzinga
News headline image
NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals. ↗
Investors should take notice ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
News headline image
Analyst Expectations For Biomarin Pharmaceutical's Future ↗
 
Via Benzinga
News headline image
3 Oversold Stocks with Big RSI Rebound Potential
Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them. 
Via MarketBeat
Topics Economy
News headline image
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced. ↗
Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability. 
Via Chartmill
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today ↗
 
Via Benzinga
News headline image
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest ↗
 
Via Benzinga
News headline image
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest ↗
 
Via Benzinga
News headline image
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish ↗
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... 
Via Benzinga
News headline image
Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents. ↗
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
News headline image
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock ↗
 
Via Benzinga
News headline image
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term ↗
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits. 
Via Benzinga
News headline image
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug ↗
The companies could soon face off in the growth treatment market for children with a genetic disorder. 
Via Investor's Business Daily
News headline image
FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
News headline image
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027 ↗
BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth. 
Via Benzinga
News headline image
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings) ↗
 
Via Benzinga
News headline image
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In ↗
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
News headline image
NASDAQ:BMRN is showing good growth, while it is not too expensive. ↗
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24 ↗
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Aug. 19-23, 2024. 
Via Talk Markets
News headline image
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.